Patents by Inventor Mohammad A. Heidaran

Mohammad A. Heidaran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240011053
    Abstract: Mental diseases include a heterogenous array of diseases that affect brain function. Evidence suggests that some of more serious conditions that lead to suicide may have some genetic and epigenetic determinants. Single Nucleotide Polymorphism (SNPs) have been identified that correlate with a variety of mental conditions and diseases. In this patent application we describe a method by which subjects with life threatening mental health disease can be identified using Single Nucleotide Polymorphism (SNP) analysis and such associated SNPs is corrected using in vivo genome editing technologies.
    Type: Application
    Filed: June 13, 2022
    Publication date: January 11, 2024
    Inventor: Mohammad A Heidaran
  • Publication number: 20230090316
    Abstract: The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.
    Type: Application
    Filed: November 21, 2022
    Publication date: March 23, 2023
    Applicant: Celularity Inc.
    Inventors: Mohammad A. HEIDARAN, Robert J. HARIRI, Kristine Erickson Johnson
  • Publication number: 20220259563
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: April 29, 2022
    Publication date: August 18, 2022
    Applicant: Celularity Inc.
    Inventors: Robert J. HARIRI, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20210121452
    Abstract: Provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising contacting the tumor cells, or administering to the individual, placental perfusate, placental perfusate cells, or natural killer cells, e.g., placenta-derived intermediate natural killer cells, with an immunomodulatory compound or thalidomide.
    Type: Application
    Filed: June 2, 2020
    Publication date: April 29, 2021
    Applicant: Celularity Inc.
    Inventors: Xiaokui ZHANG, LIn KANG, Mohammad A. HEIDARAN, Stephen JASKO, Andrew ZEITLIN, Ajai PAL, Robert J. HARIRI
  • Publication number: 20210032596
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Application
    Filed: March 12, 2020
    Publication date: February 4, 2021
    Applicant: Celularity, Inc.
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
  • Publication number: 20190330592
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 31, 2019
    Applicant: Celularity, Inc.
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Publication number: 20190321413
    Abstract: The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.
    Type: Application
    Filed: May 30, 2019
    Publication date: October 24, 2019
    Applicant: CELULARITY, INC.
    Inventors: Mohammad A. Heidaran, Robert J. Hariri, Kristine Erickson Johnson
  • Publication number: 20170240860
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Application
    Filed: October 28, 2015
    Publication date: August 24, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
  • Publication number: 20170002322
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: September 12, 2016
    Publication date: January 5, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Patent number: 9464274
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: October 11, 2016
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20160287635
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Application
    Filed: November 16, 2015
    Publication date: October 6, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20160151425
    Abstract: Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.
    Type: Application
    Filed: February 2, 2016
    Publication date: June 2, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Sascha D. Abramson, Marian Guelakis, Mohammad A. Heidaran, Kristen Labazzo, Shmuel Yaccoby
  • Patent number: 9216200
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: December 22, 2015
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Patent number: 9200253
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: December 1, 2015
    Assignee: Anthrogenesis Corporation
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa R. Voskinarian-Berse, Stewart Ernest Abbott
  • Publication number: 20150072425
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: November 18, 2014
    Publication date: March 12, 2015
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Patent number: 8926964
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: January 6, 2015
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20140322177
    Abstract: Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.
    Type: Application
    Filed: March 18, 2014
    Publication date: October 30, 2014
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Sascha D. Abramson, Marian Guelakis, Mohammad A. Heidaran, Kristen Labazzo, Shmuel Yaccoby
  • Patent number: 8728805
    Abstract: Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: May 20, 2014
    Assignee: Anthrogenesis Corporation
    Inventors: Sascha D. Abramson, Marian Guelakis, Mohammad A. Heidaran, Kristen Labazzo, Shmuel Yaccoby
  • Publication number: 20140093488
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Application
    Filed: August 13, 2012
    Publication date: April 3, 2014
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Patent number: 8638256
    Abstract: The present disclosure relates to a method for determining the position of a WLAN positioning system (WPS) and satellite positioning system (SPS) enabled device. The method can include determining an initial WPS position of the device using WPS, calculating an error region around the initial WPS position of the device, dividing the error region into a plurality of points, obtaining satellite measurements from at least two satellites in view of the device, determining a variation in a receiver clock bias for each point within the error region based on the satellite measurements from at least two satellites, selecting the point with the lowest variation in the receiver clock bias, and determining whether or not to use the point with the lowest variation in receiver clock bias to refine the initial WPS position of the device.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: January 28, 2014
    Assignee: Skyhook Wireless, Inc.
    Inventors: Farshid Alizadeh-Shabdiz, Mohammad A. Heidaran